SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVerici Dx Regulatory News (VRCI)

Share Price Information for Verici Dx (VRCI)

Share Price is delayed by 15 minutes
Get Live Data
0.375    0.00 (0.00%)
Bid:
0.35
Ask:
0.40
Spread: 0.05 (14.286%)
Market Cap: £8.30m
VRCI Live PriceLast checked at - London Stock Exchange

Intraday Verici Dx Share Chart

Holding(s) in Company

18 Mar 2022 17:13

RNS Number : 3425F
Verici Dx PLC
18 March 2022
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Verici DX plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

EKF Diagnostics Holdings Plc

City and country of registered office (if applicable)

Cardiff, United Kingdom

4. Full name of shareholder(s) (if different from 3.)v

Name

EKF Diagnostics Holdings Plc

City and country of registered office (if applicable)

Cardiff, United Kingdom

5. Date on which the threshold was crossed or reachedvi:

14 March 2022

6. Date on which issuer notified (DD/MM/YYYY):

17 March 2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

5.77%

5.77%

9,820,838

Position of previous notification (if

applicable)

1.89%

1.89%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary shares GB00BM8HZD43

9,820,838

5.77%

SUBTOTAL 8. A

9,820,838

5.77%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

See Section 4

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

Figures are based on total voting rights of 170,319,245

 

Place of completion

Avon House, 19 Stanwell Road, Penarth, Cardiff, CF64 2EZ

Date of completion

17 March 2022

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFLDVLITLIF
Date   Source Headline
12th Jun 20267:00 amRNSResult of WRAP Retail Offer
8th Jun 20261:52 pmRNSPublication of Circular & Notice of GM
8th Jun 20267:00 amRNSWRAP Retail Offer for up to £200,000
5th Jun 20265:41 pmRNSResult of Placing & raising gross proceeds c£2.5m
5th Jun 202611:40 amRNSProposed Fundraising via Placing
4th Jun 20263:40 pmRNSHolding(s) in Company
2nd Jun 202612:41 pmRNSHolding(s) in Company
2nd Jun 20267:00 amRNSAMA grants additional CPT® Code for ProtegaTM
2nd Jun 20267:00 amRNS-RStudy validating economic advantages of PTRA test
27th May 20264:04 pmRNSHolding(s) in Company
22nd May 20263:53 pmRNSHolding(s) in Company
19th May 20267:00 amRNSClinical study validating PTRA test published
13th May 20264:06 pmRNSHolding(s) in Company
11th May 20262:31 pmRNSHolding(s) in Company
11th May 202611:23 amRNSHolding(s) in Company
30th Apr 20264:30 pmRNSHolding(s) in Company
24th Apr 20265:19 pmRNSHolding(s) in Company
16th Apr 20267:00 amRNSPositive Q1 Trading Update
10th Apr 20263:24 pmRNSHolding(s) in Company
7th Apr 20265:20 pmRNSHolding(s) in Company
31st Mar 20267:00 amRNSBoard Change
5th Feb 20267:01 amRNSFY25 Trading Update
5th Feb 20267:00 amRNSAgreement with BCBS of Illinois for Tutivia™
12th Nov 20257:00 amRNS-RCompletion of CAP accreditation audit
6th Nov 20257:00 amRNSProvider Participation Agreement with Prime Health
3rd Nov 20257:00 amRNS-RCompletion of ISO 27001 surveillance audit
30th Oct 20257:00 amRNSOptions revision & Grant of new share options
6th Oct 20257:01 amRNSBoard Changes
6th Oct 20257:00 amRNSUpdate on Tutivia™ test adoption
1st Oct 20254:55 pmRNSHolding(s) in Company
30th Sep 20257:00 amRNSHalf-year Report
1st Aug 202510:40 amRNSHolding(s) in Company
31st Jul 20255:33 pmRNSHolding(s) in Company
31st Jul 20255:28 pmRNSHolding(s) in Company
31st Jul 20253:24 pmRNSHolding(s) in Company
31st Jul 20257:00 amRNSTutivia™ abstracts for World Transplant Congress
30th Jul 20252:32 pmRNSHolding(s) in Company
30th Jul 20252:26 pmRNSHolding(s) in Company
30th Jul 20257:00 amRNSResult of Annual General Meeting
29th Jul 20257:00 amRNSResult of WRAP Retail Offer
28th Jul 20255:19 pmRNSHolding(s) in Company
28th Jul 20254:55 pmRNSHolding(s) in Company
28th Jul 202510:23 amRNSHolding(s) in Company
25th Jul 20255:22 pmRNSHolding(s) in Company
25th Jul 20251:05 pmRNSHolding(s) in Company
25th Jul 20251:04 pmRNSHolding(s) in Company
24th Jul 20252:34 pmRNSHolding(s) in Company
22nd Jul 20257:00 amRNSWRAP Retail Offer for up to £500,000
21st Jul 20253:43 pmRNSResult of Placing & Subscription
21st Jul 20257:00 amRNSProposed Fundraising

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.